<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259307</url>
  </required_header>
  <id_info>
    <org_study_id>2019-06-109</org_study_id>
    <nct_id>NCT04259307</nct_id>
  </id_info>
  <brief_title>Effect of Intensive Nutritional Support in Subacute Stroke Patient</brief_title>
  <official_title>Effect of Intensive Nutritional Support on Functional Recovery in Subacute Stroke Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proper nutritional support during early rehabilitation may be beneficial for functional
      improvements in gaining functional independence and preventing complications in stroke
      patients. However, there was no consensus of proper amount of nutritional support in stroke
      patients. In this study, the investigators aimed to clarigy the effects of the intensive
      nutritional support during comprehensive rehabilitation during subacute phase to improve
      function in patients with first-ever strokes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Korean modified Barthel Index (K-MBI) at 6 months after onset</measure>
    <time_frame>6 months after onset</time_frame>
    <description>Korean modified Barthel Index (0~100)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Stroke</condition>
  <condition>Rehabilitation</condition>
  <condition>Nutrition</condition>
  <arm_group>
    <arm_group_label>Intensive nutrition group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard nutritional support only per day for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omapone Peri 724mL or Winuf Peri 654mL</intervention_name>
    <description>Additional intravenous nutrition of 500 kcal per day for 3 weeks</description>
    <arm_group_label>Intensive nutrition group</arm_group_label>
    <other_name>Comprehensive rehabilitation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute first-ever stroke patients less than 7 days after onset

               -  more than 19 years old at stroke onset ③ stroke confirmed by brain CT or MRI

                    -  body mass index (BMI) &lt;25 before the comprehensive rehabilitation ⑤ Mini
                       Nutritional Assessment &lt; 12 before the comprehensive rehabilitation ⑥
                       Fugl-Meyer assessment &lt; 85 at 7 days after stroke onset

        Exclusion Criteria:

          -  Transient ischemic stroke

               -  Progressive or unstable stroke

                    -  Pre-existing and active major neurological disease, e.g., spinal cord
                       injury, Parkinson's disease, et al.

                         -  Pre-existing and active (e.g., on chronic medication) major psychiatric
                            disease, such as major depression, schizophrenia, bipolar disease or
                            dementia ⑤ Advanced liver, kidney, cardiac, or pulmonary disease, e.g.,
                            advanced hepatocellular carcinoma, end-stage renal failure, et al.)

                              -  A terminal medical diagnosis consistent with survival &lt; 1 year

                                   -  Diabetes mellitus, Hyperlipidemia, Metabolic syndrome, Heart
                                      failure) ⑧ Pregnant or lactating women ⑨ Prohibited from
                                      taking medication (Omapone Peri 724mL or Winuf Peri 654mL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Won Hyuk Chang, MD.,PhD.</last_name>
    <phone>82-2-3410-6068</phone>
    <email>wh.chang@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Hyuk Chang, Prof</last_name>
      <phone>82-2-3410-6068</phone>
      <email>wh.chang@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Hyuk Chang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

